BR100 Increased By (0.19%)
BR30 Increased By (0.01%)
KSE100 Increased By (0.2%)
KSE30 Increased By (0.24%)
AGHA 6.77 Increased By ▲ 0.09 (1.35%)
BECO 4.39 Increased By ▲ 0.02 (0.46%)
BML 57.01 Decreased By ▼ -0.31 (-0.54%)
BOP 30.46 Increased By ▲ 0.11 (0.36%)
CNERGY 13.16 Increased By ▲ 0.04 (0.3%)
CSIL 5.40 Decreased By ▼ -0.01 (-0.18%)
FCCL 52.85 Increased By ▲ 0.06 (0.11%)
FFL 14.83 Increased By ▲ 0.11 (0.75%)
FNEL 1.13 Increased By ▲ 0.01 (0.89%)
KEL 6.10 Increased By ▲ 0.01 (0.16%)
KOSM 5.80 Increased By ▲ 0.07 (1.22%)
LOTCHEM 26.55 Increased By ▲ 0.09 (0.34%)
MLCF 93.40 Increased By ▲ 0.24 (0.26%)
NBP 165.00 Increased By ▲ 0.34 (0.21%)
NCPL 55.67 Increased By ▲ 0.01 (0.02%)
NPL 61.19 Increased By ▲ 0.03 (0.05%)
OGDC 315.60 Decreased By ▼ -1.13 (-0.36%)
PACE 9.90 Increased By ▲ 0.03 (0.3%)
PAEL 35.70 Increased By ▲ 0.07 (0.2%)
PIBTL 14.97 Increased By ▲ 0.29 (1.98%)
PPL 225.99 Decreased By ▼ -0.92 (-0.41%)
PRL 93.30 Increased By ▲ 0.28 (0.3%)
PTC 60.45 Increased By ▲ 0.19 (0.32%)
SSGC 23.80 Decreased By ▼ -0.01 (-0.04%)
TBL 8.70 Decreased By ▼ -0.05 (-0.57%)
TELE 7.85 Increased By ▲ 0.05 (0.64%)
TPL 22.55 Increased By ▲ 0.20 (0.89%)
TPLP 12.90 Decreased By ▼ -0.07 (-0.54%)
TREET 22.26 Increased By ▲ 0.10 (0.45%)
TRG 56.89 Increased By ▲ 0.33 (0.58%)
Topic

US FDA

US FDA expected to authorize Pfizer vaccine for 12-15-year-olds soon

US FDA expected to authorize Pfizer vaccine for 12-15-year-olds soon

Published 05 May, 2021 06:26pm
  • The approval is highly anticipated after the drugmaker said in March the vaccine was found to be safe, effective and produced a robust antibody responses in 12- to 15-year-olds in a clinical trial.
  • The vaccine has already been cleared in the United States for those aged 16 and above.
Lilly asks FDA to not allow lone use of COVID-19 drug bamlanivimab

Lilly asks FDA to not allow lone use of COVID-19 drug bamlanivimab

Published 16 Apr, 2021 05:45pm
  • The request made to the US Food and Drug Administration is not due to any new safety issues, but in response to the new variants in the country that could be resistant to bamlanivimab when used alone, the drugmaker said in a statement.
  • Hospitals with bamlanivimab supply should now order etesevimab to pair with it, Lilly said.
Loading...